NFKB1 and plasma cell myeloma: Ixazomib can effectively inhibit both activation pathways of NF-κB in MM stromal cells.554 Ixazomib is often used in combination with other anticancer drugs and has shown significant efficacy in clinical trials for the treatment of multiple myeloma.